Mobile

A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metas...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000544-86

A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare progression-free survival (PFS) of randomised metastatic RCC patients receiving sorafenib 400 mg bid versus standard therapy (interferon alpha-2a) as a first-line therapy.

Critère d'inclusion

  • unresectable and/or metastatic renal cell carcinoma

Liens